BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  iTeos and GSK Mull Future of Anti-TIGIT Candidate After Genentech Flop

  Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.

  May 13, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  FDA Approves Oral Version of Established ALS Drug Radicava

  The U.S. Food and Drug Administration (FDA) has approved Mitsubishi Tanabe Pharma America’s oral alternative to its own treatment for amyotrophic lateral sclerosis (ALS).

  May 13, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

  Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio’s pediatric methylmalonic acidemia study is back up and running and another look at Roche’s TIGIT flop.

  May 13, 2022

   · 

  7 min read

   · 

  Mark Terry
• 

  MIT Study: Brain Circuit in Anterior Thalamus is Critical for Memory

  A study by researchers at the Massachusetts Institute of Technolog (MIT) have found a brain circuit in the anterior thalamus that is critical for memory function.

  May 13, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Drug Development

  Marinus on Track to Capitalize on Recent Seizure Drug Approval

  Marinus shared positive news in its financial report for the first quarter, led by updates from its Phase III trial on a drug for RSE and research efforts for rare diseases.

  May 13, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Biotech Bay

  BridgeBio Augments Comeback Week with Sale of Priority Review Voucher

  BridgeBio said it would sell the voucher for $110 million but did not disclose the identity of the company planning to acquire the voucher.

  May 13, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  UCB Psoriasis Drug Will Need to Wait for US Approval

  The rejection appears to be related to pre-approval inspection issues that need to be resolved before it can be approved.

  May 13, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Pharm Country

  Yale Researchers are Quantifying Genetic and Environmental Factors in Cancer

  Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.

  May 13, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Editas, Neurocrine Snag Orphan Drug Designations as Congressional Debate Continues

  U.S. Food and Drug Administration(FDA) has granted Orphan Drug designations to Editas Medicine and Neurocrine Biosciences.

  May 13, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Universal Antivirals Could be the Future for Preventing Pandemics

  Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.

  May 13, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.